Clinical trial · Observational
Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the Fate of the Patients with Good CAP Grade
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Neoadjuvant treatment (NAT) is increasingly used in managing pancreatic ductal adenocarcinoma (PDAC), necessitating dependable methods to evaluate tumor response. 2. Among various pathological tumor regression grading systems, the College of American Pathologists (CAP) system is commonly used to predict chemo-responsiveness and survival. 3. This study aimed to analyze long-term survival outcomes based on pathologic response using the CAP grade after NAT in PDAC and to identify clinicopathologic factors that influence a favorable pathologic response.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoadjuvant Therapy | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Pathological Complete Response | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neoadjuvant therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- CAP grade 0
- description
- No viable cancer cells in pancreatic resection specimen with neoadjuvant therapy.
- interventionNames
- Drug: neoadjuvant therapy
- label
- CAP grade 1
- description
- Single cells or rare small groups of cancer cells in pancreatic resection specimen with neoadjuvant therapy.
- interventionNames
- Drug: neoadjuvant therapy
- label
- CAP grade 2
- description
- Residual cancer with evident tumor regression in pancreatic resection specimen with neoadjuvant therapy.
- interventionNames
- Drug: neoadjuvant therapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (aged \>18 years) who underwent pancreatic resection after NAT at a single center between January 2009 and December 2023. * Patients were initiated on NAT after confirming PDAC diagnosis based on pathological examination. Exclusion Criteria: * Patients without a reported CAP grade * Patients who underwent palliative surgery * Patients who received NAT outside the specified protocol due to incomplete information.
References
Publications (0)
Data not yet available